OVID News and Press, Ovid Therapeutics Inc. From 08/04/20

At $6.75/share, Ovid Therapeutics Inc. ( OVID ) has a fully diluted market cap of ~$430MM. After recent receipt of $20MM as an upfront payment from a new commercial partner, OVID has an approximate cash balance of $50MM. With $0 debt, OVID's enterprise valuation is therefore approximately $380...

The lies we tell other people are nothing to the lies we tell ourselves .”― Derek Landy This week’s covered call opportunity is around a small biotech concern with a slew of upcoming trial readouts in the second half of 2020. A full analysis and investment recommendat...

Investing in innovative drugs and therapies that treat patients with highly unmet medical needs can be a rewarding venture. Indeed, year to date, the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) has returned nearly 20%. During the same period, the S&P 500 index has gained just 1...

Ovid Therapeutics (NASDAQ: OVID )   +4.7%  PM, has announced a research collaboration and license agreement with University of Connecticut School of Medicine (UConn) for the development of a next-gen short hairpin RNA (shRNA) based therapeutic for Angelman syndrome. ...

Ovid to collaborate with renowned molecular geneticist and Angelman syndrome expert Stormy J. Chamberlain, Ph.D., to advance a short hairpin RNA (shRNA)-based therapeutic with the goal of addressing the underlying genetic cause of Angelman syndrome Ovid and UConn to collaborate on gene...

Shares of Ovid Therapeutics (NASDAQ: OVID) have more than doubled over the past four months, a performance the clinical-stage biotech company owes in part to a positive rating from an analyst. In March and again in June , Ladenburg Thalmann analyst Michael Higgins gave the stock a $20 pri...

Ovid Therapeutics (NASDAQ: OVID ) inks an agreement with Italian drugmaker Angelini Pharma S.p.A. for the development, manufacture and commercialization of OV101 (gaboxadol) for the potential treatment of Angelman syndrome in the EU, Switzerland, Turkey, UK and Russia. More news on: ...

Angelini Pharma obtains exclusive development, manufacturing and commercialization rights to OV101 (gaboxadol) for the potential treatment of Angelman syndrome in the European Union and other countries in the European Economic Area (Switzerland, Turkey and the United Kingdom) and Russia ...

NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has been added to the Russell 2000 ® and th...

Gainers:  APYX +35.1% . ALLO +4.3% . NRZ +3.4% . MYOV +2.9% . CMCL +2.8% . More news on: Apyx Medical Corporation, Allogene Therapeutics, Inc., New Residential Investment Corp., Stocks on the move, , Read more ...